All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity - Follow-ons and Rights issues

Bavarian Nordic to raise €387m to fund GSK vaccines purchase

Copenhagen_PA_575_375

Danish pharmaceuticals company Bavarian Nordic has announced an Nkr2.8bn (€378m) rights issue to fund its acquisition of GlaxoSmithKline’s commercial and manufacturing rights to Rabipur, a treatment for rabies, and Encepur, a vaccine against tick-borne encephalitis.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree